Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032726442> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2032726442 endingPage "2013" @default.
- W2032726442 startingPage "2009" @default.
- W2032726442 abstract "Some patients with rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis are resistant to inhibitors of interleukin-1 and tumour necrosis factor. Raised levels of interleukin-6 are associated with both these conditions. Tocilizumab is a humanised monoclonal antibody that binds to both forms of interleukin-6 receptor that has recently been used in Phase III trials in rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis.The study conducted an evaluation of Phase III trials with tocilizumab.In the Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders the primary efficacy end-point was the proportion of subjects with a 20% improvement in their rheumatoid arthritis signs and symptoms according to the American College of Rheumatology criteria and, at 24 weeks, this value was 26% with placebo and was increased to 48 and 59% with tocilizumab at 4 and 8 mg respectively. In the trial of tocilizumab in systemic-onset juvenile idiopathic arthritis, the primary end-point in the open-label lead-in was the proportion of subjects achieving an American College of Rheumatology Pediatric 30 response and 91% of subjects had achieved this at 6 weeks. This response was maintained by the majority of subjects being treated with tocilizumab during a 12-week double-blind trial and 48 weeks of open trial follow-up. Small numbers of subjects developed infections in both studies.Provided long-term safety can be established, tocilizumab will probably become part of the treatment for rheumatoid arthritis and may become a major breakthrough for the treatment of systemic-onset juvenile idiopathic arthritis." @default.
- W2032726442 created "2016-06-24" @default.
- W2032726442 creator A5071085963 @default.
- W2032726442 date "2008-07-16" @default.
- W2032726442 modified "2023-09-24" @default.
- W2032726442 title "Is tocilizumab an option for the treatment of arthritis?" @default.
- W2032726442 cites W1994860638 @default.
- W2032726442 cites W2012942026 @default.
- W2032726442 cites W2022713850 @default.
- W2032726442 cites W2046628605 @default.
- W2032726442 cites W2052604117 @default.
- W2032726442 cites W2065287600 @default.
- W2032726442 cites W2072274829 @default.
- W2032726442 cites W2110995918 @default.
- W2032726442 cites W2120852203 @default.
- W2032726442 cites W2125212735 @default.
- W2032726442 cites W2150952126 @default.
- W2032726442 doi "https://doi.org/10.1517/14656566.9.11.2009" @default.
- W2032726442 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18627338" @default.
- W2032726442 hasPublicationYear "2008" @default.
- W2032726442 type Work @default.
- W2032726442 sameAs 2032726442 @default.
- W2032726442 citedByCount "2" @default.
- W2032726442 countsByYear W20327264422012 @default.
- W2032726442 countsByYear W20327264422016 @default.
- W2032726442 crossrefType "journal-article" @default.
- W2032726442 hasAuthorship W2032726442A5071085963 @default.
- W2032726442 hasConcept C11988809 @default.
- W2032726442 hasConcept C126322002 @default.
- W2032726442 hasConcept C142724271 @default.
- W2032726442 hasConcept C198451711 @default.
- W2032726442 hasConcept C203092338 @default.
- W2032726442 hasConcept C204787440 @default.
- W2032726442 hasConcept C27081682 @default.
- W2032726442 hasConcept C2777077863 @default.
- W2032726442 hasConcept C2777178219 @default.
- W2032726442 hasConcept C2777575956 @default.
- W2032726442 hasConcept C2778690821 @default.
- W2032726442 hasConcept C2781059491 @default.
- W2032726442 hasConcept C535046627 @default.
- W2032726442 hasConcept C71924100 @default.
- W2032726442 hasConceptScore W2032726442C11988809 @default.
- W2032726442 hasConceptScore W2032726442C126322002 @default.
- W2032726442 hasConceptScore W2032726442C142724271 @default.
- W2032726442 hasConceptScore W2032726442C198451711 @default.
- W2032726442 hasConceptScore W2032726442C203092338 @default.
- W2032726442 hasConceptScore W2032726442C204787440 @default.
- W2032726442 hasConceptScore W2032726442C27081682 @default.
- W2032726442 hasConceptScore W2032726442C2777077863 @default.
- W2032726442 hasConceptScore W2032726442C2777178219 @default.
- W2032726442 hasConceptScore W2032726442C2777575956 @default.
- W2032726442 hasConceptScore W2032726442C2778690821 @default.
- W2032726442 hasConceptScore W2032726442C2781059491 @default.
- W2032726442 hasConceptScore W2032726442C535046627 @default.
- W2032726442 hasConceptScore W2032726442C71924100 @default.
- W2032726442 hasIssue "11" @default.
- W2032726442 hasLocation W20327264421 @default.
- W2032726442 hasLocation W20327264422 @default.
- W2032726442 hasOpenAccess W2032726442 @default.
- W2032726442 hasPrimaryLocation W20327264421 @default.
- W2032726442 hasRelatedWork W1987294331 @default.
- W2032726442 hasRelatedWork W2019704288 @default.
- W2032726442 hasRelatedWork W2045253669 @default.
- W2032726442 hasRelatedWork W2098703756 @default.
- W2032726442 hasRelatedWork W2150952126 @default.
- W2032726442 hasRelatedWork W2736593664 @default.
- W2032726442 hasRelatedWork W2766107824 @default.
- W2032726442 hasRelatedWork W2783466784 @default.
- W2032726442 hasRelatedWork W2980857560 @default.
- W2032726442 hasRelatedWork W2996380604 @default.
- W2032726442 hasVolume "9" @default.
- W2032726442 isParatext "false" @default.
- W2032726442 isRetracted "false" @default.
- W2032726442 magId "2032726442" @default.
- W2032726442 workType "article" @default.